ABBVAbbVieSigning up patients
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Multiple Myeloma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 325 (planned)
- Started
- Jul 23, 2025
- Main results expected
- Dec 2030
- Fully finished
- Dec 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Dose-Limiting Toxicities (DLT)s of ABBV-453
Measured over: Up to Approximately 45 Months
Number of Participants with Adverse Events (AE)s
Measured over: Up to Approximately 4.5 Years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06953960 · record last updated 2026-10-27 · checked 2026-11-09 15:47 UTC